Benitec & Circuit Therapeutics

“”The undesired sensory response may be chronic pain and the RNAi may be achieved through a ddRNAi specific to Nav 1.7. The adeno-associated virus may be self-complementary. Cutaneously administering comprises intradermally or subcutaneously administering.””

Great to see our ddrnai technology being used by our exclusive licensee Circuit Therapeutics in this latest July 2019 update on their programs.

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PG01&s1=Ddrnai&OS=Ddrnai&RS=Ddrnai

Good luck all holders.